泛素一蛋白酶体系统在血液肿瘤中的研究进展  

Advances of the ubiquitin-proteasome system in hematologic neoplasms

作　　者：曹海武[1] 王智[1] 柳萍[1] 李凌浩[1] 赵晓红[1] 

机构地区：[1]南京医科大学附属无锡市第二人民医院血液科,江苏无锡214002

出　　处：《海南医学》2014年第24期3672-3674,共3页Hainan Medical Journal

基　　金：无锡市医管中心重大(协作)项目(编号:YGZX1119)

摘　　要：泛素-蛋白酶体系统是真核细胞内重要的蛋白质质控系统，主要降解细胞内80%-90%泛素化的蛋白质，并调节炎症、细胞增生与分化、信号转导、细胞周期进程、转录调控、抗原提呈、免疫应答、细胞凋亡和DNA修复等各种细胞生物学功能。当泛素-蛋白酶体系统对靶蛋白的降解功能失常时，可以导致血液肿瘤的发生。研究泛素-蛋白酶体系统异常的特异性关键蛋白，将有可能发现血液系统肿瘤的新的诊断标志，为临床治疗提供新的分子靶点。The ubiquitin-proteasome system is an important protein quality control system in eukaryotic cells, mainly degrading 80%-90%ubiquitylated proteins in cells, and regulating many kinds of biological functions in cells such as inflammation, cell proliferation and differentiation, signal transduction, cell cycle progression, transcrip-tional regulation, antigen presentation, immune response, apoptosis and DNA repairing. The malfunction of ubiqui-tin-proteasome system in the targeted proteins could lead to the occurrence of hematologic neoplasm. The research of the specific key protein in abnormal ubiquitin-proteasome system will help us find a new diagnostic marker of hemato-logical tumors and provide a new molecular target for the clinical treatment.

关 键 词：泛素-蛋白酶体系统 蛋白质降解 血液肿瘤 

分 类 号：R733[医药卫生—肿瘤]